A Phase 2 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging in a Defined Special Population - Obese Subjects (BMI > or Equal to 30 kg/m2)
Phase of Trial: Phase II
Latest Information Update: 08 Jan 2016
At a glance
- Drugs Salmeterol (Primary)
- Indications Subcutaneous fat disorders
- Focus Adverse reactions
- Sponsors Neothetics
- 23 Dec 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 13 Oct 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 05 Oct 2015 New trial record